Compare SIBN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | RLMD |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.3M | 661.9M |
| IPO Year | 2018 | 2012 |
| Metric | SIBN | RLMD |
|---|---|---|
| Price | $15.39 | $6.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $23.88 | $12.40 |
| AVG Volume (30 Days) | 488.9K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.33 | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,301,000.00 | $13,070.00 |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $14.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 21.53 | ★ 154.83 |
| 52 Week Low | $11.48 | $0.52 |
| 52 Week High | $21.89 | $8.00 |
| Indicator | SIBN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.79 | 44.94 |
| Support Level | $14.62 | $6.17 |
| Resistance Level | $15.98 | $7.46 |
| Average True Range (ATR) | 0.62 | 0.38 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 85.28 | 43.55 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.